24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis

https://doi.org/10.1016/j.ijcard.2014.05.013Get rights and content

Abstract

Objective

Once-daily aspirin is standard treatment, but recent studies point towards increased platelet function at the end of the dosing interval. Stent thrombosis (ST) has been linked with reduced antiplatelet effect of aspirin, so we investigated if platelet inhibition by aspirin declines through 24 h in patients with previous definite ST. Furthermore, we explored whether increased levels of immature platelets and thrombopoietin are associated with a particularly rapid recovery of platelet function.

Methods

This case–control study included 50 patients with previous definite ST matched with 100 patients with stable coronary artery disease and 50 healthy volunteers. All participants were on aspirin 75 mg/day mono antiplatelet therapy. Platelet aggregation was measured 1 and 24 h after aspirin intake using platelet aggregometry (Multiplate® Analyzer). Cyclooxygenase-1 activity, platelet activation, immature platelets, and thrombopoietin were measured.

Results

Platelet aggregation increased by 109 ± 150 (arachidonic acid) and 47 ± 155 (collagen) aggregation units per minute from 1 to 24 h after aspirin intake (p-values < 0.0001) with corresponding increases in thromboxane B2 (5.6 ± 5.1 ng/ml, p < 0.0001) and soluble P-selectin (6.2 ± 15.5 ng/ml, p < 0.0001). Platelet aggregation increased equally in all groups, but patients with previous ST displayed the highest levels of platelet aggregation at 24 h (p-values  0.05) and the highest levels of immature platelets (p < 0.01) and thrombopoietin (p < 0.0001).

Conclusions

Platelet inhibition declined significantly during the 24-hour dosing interval in aspirin-treated patients with previous definite ST or stable coronary artery disease and in healthy individuals. Increased levels of immature platelets and thrombopoietin were observed in patients with previous definite ST.

Introduction

Low-dose aspirin reduces by one-fifth the risk of recurrent arterial thrombosis in patients with coronary artery disease (CAD), and international clinical guidelines recommend that low-dose aspirin is administered once daily in these patients [1]. This treatment strategy reflects that aspirin is considered to sustain adequate platelet inhibition through the 24-hour dosing interval. However, emerging evidence questions this assumption. Recent studies point towards a gradual attenuation of aspirin's antiplatelet effect through 24 h causing increased residual platelet aggregation [2], [3], [4], [5] and cyclooxygenase (COX) activity [4], [5], [6]. Furthermore, pharmacodynamic studies suggest that a twice-daily dosing regimen provides more consistent platelet inhibition through 24 h than does the recommended once-daily regimen [7], [8], [9].

Stent thrombosis (ST) is a devastating complication of percutaneous coronary intervention [10], and the complex pathophysiology of in-stent thrombus formation includes procedural and pharmacological factors [11]. Antiplatelet drugs are essential in maintaining stent patency and preventing stent occlusion [11]; however, in patients with a history of definite ST residual platelet aggregation during aspirin treatment is substantial [12], [13]. Patients with previous definite ST also seem to have an accelerated platelet turnover as indicated by higher levels of immature platelets [12]. Immature platelets are large, reticulated and highly reactive, which renders them prone to thrombus formation. Moreover, given aspirin's plasma half-life of only 20 min, newly formed platelets may produce thromboxane due to uninhibited COX-1 activity. Recent studies have associated an accelerated platelet turnover with increased residual platelet aggregation in different cardiovascular settings [12], [14], [15], [16], [17]. Furthermore, differences in platelet production may contribute to variability in residual platelet aggregation levels because thrombopoietin, the primary hormonal regulator of platelet production, directly affects platelet aggregability [18].

We hypothesized that platelet inhibition by low-dose aspirin is reduced during the standard 24-hour dosing interval. Based on previous studies, this may particularly be the case in patients with previous definite ST. Moreover, we explored whether the recovery of platelet aggregation is particularly pronounced in patients with an accelerated platelet turnover.

Section snippets

Methods

The study was conducted in accordance with the Helsinki II Declaration, and the study protocol was approved by the Central Denmark Region Committees on Biomedical Research Ethics (#2011-0231). Written informed consent was obtained from all participants, of which only healthy volunteers were remunerated for their participation.

Results

Baseline characteristics, concomitant drug use and cardiovascular risk factors are shown in Table 1, and procedural characteristics are shown in Table 2. Participants were 64 ± 11 years old and predominantly men (91%). ST and CAD patients were carefully matched with respect to age, sex and diabetes, but there was an excess of previous myocardial infarction in the ST group explained by the intended selection of stable CAD patients with no history of myocardial infarction. In the ST group, 33

Discussion

This study is the largest to investigate the 24-hour effect of aspirin in a study population including patients with previous definite ST. Overall, platelet aggregation, COX-1 activity and platelet activation increased through 24 h, whereas platelet turnover and thrombopoietin levels remained fairly constant suggesting that aspirin treatment does not directly influence these parameters. However, platelet turnover and thrombopoietin levels were significantly elevated in ST patients, perhaps

Conclusions

Platelet inhibition by aspirin declined significantly during the 24-hour dosing interval in patients with previous definite ST, stable CAD patients and healthy individuals. This study suggests that not all patients derive optimal cardiovascular protection from once-daily aspirin. Increased levels of platelet turnover and thrombopoietin were observed in patients with previous definite ST. This may reflect a thrombotic predisposition in these patients.

Funding

This work was supported by Aarhus University, The A.P. Møller Foundation for the Advancement of Medical Science, Gangstedfonden, and Direktør Kurt Bønnelycke & hustru Grethe Bønnelyckes Fond.

Disclosures

ELG has received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim and Pfizer and serves on advisory boards for AstraZeneca, Bayer, and Bristol-Myers Squibb. SDK has received speaker honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Iroko, Pfizer, and The Medicines Company. LOJ has received an unrestricted grant form Terumo and honoraria from AstraZeneca.

Acknowledgments

The authors thank laboratory technicians Vivi Bo Mogensen, Mai Stenulm Therkelsen, and Nasise Wami for invaluable technical assistance.

References (33)

Cited by (33)

  • Application of omics beyond the central dogma in coronary heart disease research: A bibliometric study and literature review

    2022, Computers in Biology and Medicine
    Citation Excerpt :

    This ties in with the benefits of antiplatelet drugs for CHD intervention [46]. On a related note, there have also been studies on residual platelet activity for CHD patients under aspirin treatment, via analysis of several single nucleotide polymorphisms and miRNAs [47,48]. Then again, most of these studies on platelets activity focused on upstream biological processes, and few have addressed the downstream omics [49].

  • Antiplatelet effect of aspirin during 24 h in patients with type 2 diabetes without cardiovascular disease

    2018, Thrombosis Research
    Citation Excerpt :

    Our study differs from these studies by having a homogeneous population of T2DM without CVD and a control group consisting of sex- and age-matched volunteers without diabetes. In accordance with previous studies [15,25–28], our study showed that patients treated with low-dose aspirin have a time-dependent increase in platelet aggregation through the dosing interval. Our study extends these findings to a well-controlled (HbA1c = 53 ± 12 mmol/mol) population of patients with T2DM and no previous history of CVD.

  • A 45-SNP genetic risk score is increased in early-onset coronary artery disease but independent of familial disease clustering

    2017, Atherosclerosis
    Citation Excerpt :

    The present study was a cross-sectional study in patients with early- and late-onset CAD. The recruitment of patients has previously been described in detail [22–24]. Briefly, all patients were recruited from the Western Denmark Heart Registry (WDHR) and interviewed between 2007 and 2015.

  • A brief review on high on-aspirin residual platelet reactivity

    2015, Vascular Pharmacology
    Citation Excerpt :

    An increased fraction of newly formed platelets might therefore be a potential mechanism for high-on-aspirin RPR [43]. High-on-aspirin RPR is five-fold more frequent 24 h as compared to 2 h after aspirin ingestion, and this observation has been related to inflammation, current smoking and diabetes [46,47]. The drug–drug interaction between aspirin and ibuprofen is well known to contribute to high-on-aspirin RPR [48,49].

View all citing articles on Scopus
1

This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

View full text